Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96


miR-506 regulates epithelial mesenchymal transition in breast cancer cell lines.

Arora H, Qureshi R, Park WY.

PLoS One. 2013 May 22;8(5):e64273. doi: 10.1371/journal.pone.0064273. Print 2013.


miR-221/222 targets adiponectin receptor 1 to promote the epithelial-to-mesenchymal transition in breast cancer.

Hwang MS, Yu N, Stinson SY, Yue P, Newman RJ, Allan BB, Dornan D.

PLoS One. 2013 Jun 11;8(6):e66502. doi: 10.1371/journal.pone.0066502. Print 2013.


MIR-99a and MIR-99b modulate TGF-β induced epithelial to mesenchymal plasticity in normal murine mammary gland cells.

Turcatel G, Rubin N, El-Hashash A, Warburton D.

PLoS One. 2012;7(1):e31032. doi: 10.1371/journal.pone.0031032. Epub 2012 Jan 27.


MiR-21 regulates epithelial-mesenchymal transition phenotype and hypoxia-inducible factor-1α expression in third-sphere forming breast cancer stem cell-like cells.

Han M, Wang Y, Liu M, Bi X, Bao J, Zeng N, Zhu Z, Mo Z, Wu C, Chen X.

Cancer Sci. 2012 Jun;103(6):1058-64. doi: 10.1111/j.1349-7006.2012.02281.x. Epub 2012 Apr 23.


Sinomenine inhibits breast cancer cell invasion and migration by suppressing NF-κB activation mediated by IL-4/miR-324-5p/CUEDC2 axis.

Song L, Liu D, Zhao Y, He J, Kang H, Dai Z, Wang X, Zhang S, Zan Y.

Biochem Biophys Res Commun. 2015 Aug 28;464(3):705-10. doi: 10.1016/j.bbrc.2015.07.004. Epub 2015 Jul 10.


MiR-153 inhibits epithelial-mesenchymal transition by targeting metadherin in human breast cancer.

Li W, Zhai L, Zhao C, Lv S.

Breast Cancer Res Treat. 2015 Apr;150(3):501-9. doi: 10.1007/s10549-015-3346-y. Epub 2015 Mar 21.


Antagonism of miR-21 reverses epithelial-mesenchymal transition and cancer stem cell phenotype through AKT/ERK1/2 inactivation by targeting PTEN.

Han M, Liu M, Wang Y, Chen X, Xu J, Sun Y, Zhao L, Qu H, Fan Y, Wu C.

PLoS One. 2012;7(6):e39520. doi: 10.1371/journal.pone.0039520. Epub 2012 Jun 25.


miR-381 inhibited breast cancer cells proliferation, epithelial-to-mesenchymal transition and metastasis by targeting CXCR4.

Xue Y, Xu W, Zhao W, Wang W, Zhang D, Wu P.

Biomed Pharmacother. 2017 Feb;86:426-433. doi: 10.1016/j.biopha.2016.12.051. Epub 2016 Dec 21.


Genetic and epigenetic down-regulation of microRNA-212 promotes colorectal tumor metastasis via dysregulation of MnSOD.

Meng X, Wu J, Pan C, Wang H, Ying X, Zhou Y, Yu H, Zuo Y, Pan Z, Liu RY, Huang W.

Gastroenterology. 2013 Aug;145(2):426-36.e1-6. doi: 10.1053/j.gastro.2013.04.004. Epub 2013 Apr 9.


MicroRNA-30a inhibits cell migration and invasion by downregulating vimentin expression and is a potential prognostic marker in breast cancer.

Cheng CW, Wang HW, Chang CW, Chu HW, Chen CY, Yu JC, Chao JI, Liu HF, Ding SL, Shen CY.

Breast Cancer Res Treat. 2012 Aug;134(3):1081-93. doi: 10.1007/s10549-012-2034-4. Epub 2012 Apr 4.


MiR-124 targets Slug to regulate epithelial-mesenchymal transition and metastasis of breast cancer.

Liang YJ, Wang QY, Zhou CX, Yin QQ, He M, Yu XT, Cao DX, Chen GQ, He JR, Zhao Q.

Carcinogenesis. 2013 Mar;34(3):713-22. doi: 10.1093/carcin/bgs383. Epub 2012 Dec 17.


Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer.

Ward A, Balwierz A, Zhang JD, Küblbeck M, Pawitan Y, Hielscher T, Wiemann S, Sahin Ö.

Oncogene. 2013 Feb 28;32(9):1173-82. doi: 10.1038/onc.2012.128. Epub 2012 Apr 16.


Hepatoma-derived growth factor regulates breast cancer cell invasion by modulating epithelial--mesenchymal transition.

Chen SC, Kung ML, Hu TH, Chen HY, Wu JC, Kuo HM, Tsai HE, Lin YW, Wen ZH, Liu JK, Yeh MH, Tai MH.

J Pathol. 2012 Oct;228(2):158-69. doi: 10.1002/path.3988. Epub 2012 May 23.


MiR-7, inhibited indirectly by lincRNA HOTAIR, directly inhibits SETDB1 and reverses the EMT of breast cancer stem cells by downregulating the STAT3 pathway.

Zhang H, Cai K, Wang J, Wang X, Cheng K, Shi F, Jiang L, Zhang Y, Dou J.

Stem Cells. 2014 Nov;32(11):2858-68. doi: 10.1002/stem.1795.


MicroRNA-138 modulates metastasis and EMT in breast cancer cells by targeting vimentin.

Zhang J, Liu D, Feng Z, Mao J, Zhang C, Lu Y, Li J, Zhang Q, Li Q, Li L.

Biomed Pharmacother. 2016 Feb;77:135-41. doi: 10.1016/j.biopha.2015.12.018. Epub 2015 Dec 29.


miR-520b regulates migration of breast cancer cells by targeting hepatitis B X-interacting protein and interleukin-8.

Hu N, Zhang J, Cui W, Kong G, Zhang S, Yue L, Bai X, Zhang Z, Zhang W, Zhang X, Ye L.

J Biol Chem. 2011 Apr 15;286(15):13714-22. doi: 10.1074/jbc.M110.204131. Epub 2011 Feb 22.


MicroRNA-7 inhibits epithelial-to-mesenchymal transition and metastasis of breast cancer cells via targeting FAK expression.

Kong X, Li G, Yuan Y, He Y, Wu X, Zhang W, Wu Z, Chen T, Wu W, Lobie PE, Zhu T.

PLoS One. 2012;7(8):e41523. doi: 10.1371/journal.pone.0041523. Epub 2012 Aug 2.


Wild-type p53 suppresses the epithelial-mesenchymal transition and stemness in PC-3 prostate cancer cells by modulating miR‑145.

Ren D, Wang M, Guo W, Zhao X, Tu X, Huang S, Zou X, Peng X.

Int J Oncol. 2013 Apr;42(4):1473-81. doi: 10.3892/ijo.2013.1825. Epub 2013 Feb 12.


MiR-200a inhibits epithelial-mesenchymal transition of pancreatic cancer stem cell.

Lu Y, Lu J, Li X, Zhu H, Fan X, Zhu S, Wang Y, Guo Q, Wang L, Huang Y, Zhu M, Wang Z.

BMC Cancer. 2014 Feb 12;14:85. doi: 10.1186/1471-2407-14-85.


Induction of the mesenchymal to epithelial transition by demethylation- activated microRNA-200c is involved in the anti-migration/invasion effects of arsenic trioxide on human breast cancer cells.

Si L, Jiang F, Li Y, Ye X, Mu J, Wang X, Ning S, Hu C, Li Z.

Mol Carcinog. 2015 Sep;54(9):859-69. doi: 10.1002/mc.22157. Epub 2014 Apr 14.


Supplemental Content

Support Center